rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2008-2-22
|
pubmed:abstractText |
The introduction of ready-to-use lanreotide Autogel has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1365-2265
|
pubmed:author |
pubmed-author:AtkinS LSL,
pubmed-author:BevanJ SJS,
pubmed-author:BoulouxP MPM,
pubmed-author:ChapmanJJ,
pubmed-author:DavisJ R EJR,
pubmed-author:HowlettT ATA,
pubmed-author:Newell-PriceJJ,
pubmed-author:RandevaH SHS,
pubmed-author:StewartP MPM,
pubmed-author:ViswanathAA,
pubmed-author:WassJ A HJA
|
pubmed:issnType |
Electronic
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
343-9
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:17892497-Acromegaly,
pubmed-meshheading:17892497-Adult,
pubmed-meshheading:17892497-Aged,
pubmed-meshheading:17892497-Aged, 80 and over,
pubmed-meshheading:17892497-Female,
pubmed-meshheading:17892497-Home Nursing,
pubmed-meshheading:17892497-Humans,
pubmed-meshheading:17892497-Injections, Subcutaneous,
pubmed-meshheading:17892497-Male,
pubmed-meshheading:17892497-Middle Aged,
pubmed-meshheading:17892497-Peptides, Cyclic,
pubmed-meshheading:17892497-Self Care,
pubmed-meshheading:17892497-Somatostatin,
pubmed-meshheading:17892497-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
|
pubmed:affiliation |
Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK. j.s.bevan@arh.grampian.scot.nhs.uk
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase IV
|